PSMA: A Windfall for PET/CT Imaging

4 min
Hildegard Kaulen
Published on August 23, 2017
Professor Klaus Kopka, MD and Professor Frederik Giesel, MD are responsible for planning and organization of the clinical trial that suggest pet ct imaging using 68Ga-labelled PSMA-11 could transform treating prostate cancer.
Professor Klaus Kopka, MD (left) and Professor Frederik Giesel, MD
Giesel explains that 68Ga-labelled PSMA-11 is more sensitive than the choline tracer for diagnosing recurrent prostate cancer.
Professor Frederik Giesel, MD, Vice chair of the Nuclear Medicine department and clinical trial director, University Hospital Heidelberg, Germany
PSMA is not just an excellent candidate for pet ct imaging; together with a therapeutic radionuclide it can also be used for treating prostate cancer.
Professor Klaus Kopka, MD, Head of Radiopharmaceutical Chemistry, DKFZ Heidelberg, Germany



By Hildegard Kaulen

Hildegard Kaulen, PhD, is a molecular biologist. Following positions at Rockefeller University in New York and Massachusetts General Hospital in Boston, she now works as a freelance science journalist for newspapers and scientific magazines.